Notice of Intent to Publish Funding Opportunity Announcements for Phase 2 of the U.S.-South Africa Program for Collaborative Biomedical Research (R01 and U01, Clinical Trial Optional)

Notice Number: NOT-AI-19-032

Key Dates

Release Date:January 10, 2019
Estimated Publication Date of Funding Opportunity Announcement: March 06, 2019
First Estimated Application Due Date:July 26, 2019
Earliest Estimated Award Date: April 01, 2020
Earliest Estimated Start Date: April 01, 2020

Related Announcements
RFA-AI-14-009
RFA-AI-14-010

Issued by
National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The National Institute of Allergy and Infectious Diseases (NIAID) is issuing this Notice to promote new initiatives that will solicit applications to support research under Phase 2 of the U.S.-South Africa Program for Collaborative Biomedical Research. The intent of this program is to foster, stimulate, and/or expand basic, translational, behavioral and applied research that will advance scientific discovery and engage U.S. and South African researchers working collaboratively in the areas of HIV/AIDS, HIV/AIDS-associated malignancies, and other infectious diseases.

These FOAs will utilize the R01 and U01 activity codes, and U.S. and South African investigators working in partnership will prepare and submit a single joint application. This notice is provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive applications. Details of the planned FOAs are provided below.

These FOAs are expected to be published in March 2019 with an expected application due date in July 2019.

Research Initiative Details

This Notice encourages investigators from South Africa and the U.S. to create a multidisciplinary team to begin to consider applying for these FOAs. Research areas supported under this program include: HIV/AIDS; HIV/AIDS-associated malignancies; tuberculosis; sexually transmitted infections; parasitic infections; arboviruses and emerging/re-emerging viral pathogens; and vector biology and control. Basic, translational, behavioral, clinical, preventive, or epidemiological research may be proposed under this program. Proposed research should reflect the highest possible scientific standards, as well as shared interests, international and local public health needs and priorities, and involve mutually advantageous collaborations among institutions, including participating communities and other partners. This FOAs will encourage collaboration with underrepresented scientists within South Africa.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Cancer Institute (NCI)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Mental Health (NIMH)

Funding Information

Estimated Total Funding TBD
Expected Number of Awards TBD
Estimated Award Ceiling TBD
Primary CFDA Numbers TBD

Anticipated Eligible Organizations

Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
City or township governments
Special district governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Non-domestic (non-U.S.) Entity (Foreign Organization)
Regional Organization
Applications are not being solicited at this time. 

 

Inquiries

Please direct all inquiries to:

Holly Curtis, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
240-762-1979
holly.curtis@nih.gov